PD-1/PD-L1 combined with LAG3 is associated with clinical activity of immune checkpoint inhibitors in metastatic primary pulmonary lymphoepithelioma-like carcinoma

被引：6

作者：

Zhong, Yu-Min ^{[1
,2
,3
]}

Yin, Kai ^{[2
,4
]}

Chen, Yu ^{[2
,3
]}

Xie, Zhi ^{[2
,3
]}

Lv, Zhi-Yi ^{[2
,3
]}

Yang, Jin-Ji ^{[2
]}

Yang, Xue-Ning ^{[2
]}

Zhou, Qing ^{[2
]}

Wang, Bin-Chao ^{[2
]}

Zhong, Wen-Zhao ^{[2
]}

Gao, Ling-Ling ^{[2
,4
]}

Zhou, Wen-Bin ^{[2
]}

Chen, Ji ^{[2
,4
]}

Tu, Hai-Yan ^{[2
]}

Liao, Ri-Qiang ^{[2
]}

Zhang, Dong-Kun ^{[5
]}

Zhang, Shui-Lian ^{[2
,3
]}

Lu, Dan-Xia ^{[2
,3
]}

Zheng, Hong-Bo ^{[6
]}

Zhang, Heng-Hui ^{[6
]}

Wu, Yi-Long ^{[2
]}

Zhang, Xu-Chao ^{[1
,2
,3
,4
]}

机构：

[1] Guangdong Acad Med Sci, Guangdong Prov Peoples Hosp, Guangdong Cardiovasc Inst, Guangzhou, Peoples R China

[2] Guangdong Acad Med Sci, Guangdong Prov Peoples Hosp, Guangdong Lung Canc Inst, Canc Ctr, Guangzhou, Peoples R China

[3] Guangdong Acad Med Sci, Guangdong Prov Peoples Hosp, Med Res Ctr, Guangzhou, Peoples R China

[4] Southern Med Univ, Sch Clin Med 2, Guangzhou, Peoples R China

[5] Guangdong Acad Med Sci, Guangdong Prov Peoples Hosp, Dept Thorac Surg, Guangzhou, Peoples R China

[6] Genecast Biotechnol, Dept Med Affairs, Wuxi, Peoples R China

来源：

FRONTIERS IN IMMUNOLOGY | 2022年 / 13卷

基金：

中国国家自然科学基金;

关键词：

Lymphoepithelioma-like carcinoma; PD-1; PD-L1; inhibitors; LAG3; CELL LUNG-CANCER; NIVOLUMAB; CHEMOTHERAPY; EXPRESSION; THERAPY; PD-L1; EGFR; IMMUNOTHERAPY; PEMBROLIZUMAB; MUTATION;

D O I：

10.3389/fimmu.2022.951817

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Primary pulmonary lymphoepithelioma-like carcinoma (PLELC) is an Epstein-Barr virus (EBV)-related, rare subtype of non-small-cell lung cancer (NSCLC). Immune checkpoint inhibitors (ICI) show durable responses in advanced NSCLC. However, their effects and predictive biomarkers in PLELC remain poorly understood. We retrospectively analyzed the data of 48 metastatic PLELC patients treated with ICI. Pretreated paraffin-embedded specimens (n = 19) were stained for PD-1, PD-L1, LAG3, TIM3, CD3, CD4, CD8, CD68, FOXP3, and cytokeratin (CK) by multiple immunohistochemistry (mIHC). Next-generation sequencing was performed for 33 PLELC samples. Among patients treated with ICI monotherapy (n = 30), the objective response rate (ORR), disease control rate (DCR), median progression-free survival (mPFS), and overall survival (mOS) were 13.3%, 80.0%, 7.7 months, and 24.9 months, respectively. Patients with PD-L1 >= 1% showed a longer PFS (8.4 vs. 2.1 months, p = 0.015) relative to those with PD-L1 <1%. Among patients treated with ICI combination therapy (n = 18), ORR, DCR, mPFS, and mOS were 27.8%, 100.0%, 10.1 months, and 19.7 months, respectively. Patients with PD-L1 >= 1% showed a significantly superior OS than those with PD-L1 <1% (NA versus 11.7 months, p = 0.001). Among the 19 mIHC patients, those with high PD-1/PD-L1 and LAG3 expression showed a longer PFS (19.0 vs. 3.9 months, p = 0.003). ICI also showed promising efficacy for treating metastatic PLELC. PD-L1 may be both predictive of ICI treatment efficacy and prognostic for survival in PLELC. PD-1/PD-L1 combined with LAG3 may serve as a predictor of ICI treatment effectiveness in PLELC. Larger and prospective trials are warranted to validate both ICI activity and predictive biomarkers in PLELC.This study was partly presented as a poster at the IASLC 20th World Conference on Lung Cancer 2019, 7-10 September 2019, Barcelona, Spain.

引用

页数：12

共 50 条

[1] Tumor Microenvironment Is Associated with Efficacy of PD-1/PD-L1 Inhibitors in Patients with Primary Pulmonary Lymphoepithelioma-Like Cancer
Yin, K.
Xie, Z.
Lv, Z.
Yang, J.
Yang, X.
Zhou, Q.
Zhong, W.
Li, L.
Feng, H.
Guo, W.
Lu, D.
Chen, Y.
Yan, W.
Wu, Y.
Zhang, X.
JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S456 - S457
[2] Expression of PD-L1/PD-1 in lymphoepithelioma-like carcinoma of the thymus
Suster, David
Pihan, German
Mackinnon, Alexander C.
Suster, Saul
MODERN PATHOLOGY, 2018, 31 (12) : 1801 - 1806
[3] PD-1/PD-L1 Inhibition Might be an Option for the Treatment of Advanced Primary Pulmonary Lymphoepithelioma-Like Carcinoma
Yin, K.
Xie, Z.
Yang, X.
Guo, W.
Chen, Y.
Yan, W.
Yang, J.
Zhou, Q.
Zhong, W.
Wu, Y.
Zhang, X.
JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S742 - S742
[4] PD-L1 expression in pulmonary lymphoepithelioma-like carcinoma: is it a prognostic biomarker?
Li, Wen
Zhang, Xinyue
Huang, Jianping
Yang, Yinghong
TRANSLATIONAL LUNG CANCER RESEARCH, 2022,
[5] EBV-positive Primary Pulmonary Lymphoepithelioma-like Carcinoma Response to PD-L1 Blockade
Narayanan, Anand
Knollmann, Friedrich D.
Walby, Julie Ann S.
Lim, Steffany
Gandara, David R.
Riess, Jonathan W.
CLINICAL LUNG CANCER, 2019, 20 (03) : E238 - E241
[6] Neurological adverse events associated with PD-1/PD-L1 immune checkpoint inhibitors
Zhou, Yanting
Li, Hongyan
FRONTIERS IN NEUROSCIENCE, 2023, 17
[7] Bioactive Macrocyclic Inhibitors of the PD-1/PD-L1 Immune Checkpoint
Magiera-Mularz, Katarzyna
Skalniak, Lukasz
Zak, Krzysztof M.
Musielak, Bogdan
Rudzinska-Szostak, Ewa
Berlicki, Lukasz
Kocik, Justyna
Grudnik, Przemyslaw
Sala, Dominik
Zarganes-Tzitzikas, Tryfon
Shaabani, Shabnam
Doemling, Alexander
Dubin, Grzegorz
Holak, Tad A.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION, 2017, 56 (44) : 13732 - 13735
[8] Efficacy of PD-1/PD-L1 immune checkpoint inhibitors and PD-L1 testing in thoracic cancers
Duruisseaux, Michael
Rouquette, Isabelle
Adam, Julien
Cortot, Alexis
Cazes, Aurelie
Gibault, Laure
Damotte, Diane
Lantuejoul, Sylvie
ANNALES DE PATHOLOGIE, 2017, 37 (01) : 61 - 78
[9] PD-1/PD-L1 immune checkpoint inhibitors in glioblastoma: clinical studies, challenges and potential
Yang, Tianrui
Kong, Ziren
Ma, Wenbin
HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2021, 17 (02) : 546 - 553
[10] Neoadjuvant PD-1/PD-L1 Immune Checkpoint Inhibitors in Solid Tumors
Zhao, S.
Li, X.
Wang, S.
Wang, Y.
Huang, D.
Da, Y.
Song, Z.
Chen, J.
Manegold, C.
Peng, L.
Xu, S.
JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S651 - S651

← 1 2 3 4 5 →